论文部分内容阅读
目的 探讨蚓激酶胶囊治疗糖尿病(DM)并发冠心病的疗效。方法 对两组DM并发冠心病患者,加服蚓激酶组及不服蚓激酶组进行疗效对比。结果 蚓激酶组有效率为96％,纤维蛋白原降低,凝血时间延长,治疗前后比较有非常显著性差异;对照组有效率为75％,前后比较有显著性差异。治疗后两组比较有非常显著性差异,P<0.01。本组病例未见出血、皮疹及肝肾功能异常等不良反应。结论 蚓激酶胶囊是治疗DM冠心病安全有效的药物,在降糖、降脂、阿司匹林抗凝的基础上加服蚓激酶胶囊,疗效有协同相加效果。
Objective To investigate the efficacy of lumbrokinase capsule in the treatment of diabetes mellitus (DM) complicated with coronary heart disease. Methods The efficacy of two groups of patients with DM complicated with coronary heart disease, plus lumbrokinase group and not receiving lumbrokinase group were compared. Results The effective rate of lumbrokinase group was 96%, fibrinogen decreased, clotting time prolonged, before and after treatment there was a very significant difference; the control group was 75% effective, before and after significant differences. After treatment there was a significant difference between the two groups, P <0.01. No bleeding, rash and abnormal liver and kidney function were observed in this group of patients. Conclusion Lumbukinase capsule is a safe and effective drug for the treatment of coronary heart disease (DM). On the basis of hypoglycemic, lipid-lowering and aspirin anticoagulant, lumbrokinase capsules are supplemented with lumbrokinase capsules, and the efficacy is synergistic and additive.